source
- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.BioSpace · 8d ago↗ source
- Trump administration says it’s deferring $1B in Medicaid payments to California and MinnesotaThe Trump administration said it was deferring more than $1 billion in Medicaid payments to Minnesota and California because of “suspected fraud and noncompliance.”STAT · 8d ago↗ source
- STAT+: Rare disease drugmakers try to avoid Trump price cutsPlus, GOP voters want a crackdown on health care fraud, and how PBMs are skirting state laws.STAT · 8d ago